NHG-Richtlijnen
NHG-Standaard
M62
3.1
In herziening
april 2019
mei 2019
P. Psychische problemen

Begrippen

Naar Volledige tekst ›

Richtlijnen diagnostiek

Naar Volledige tekst ›

Signalen

Naar Volledige tekst ›

Anamnese

Naar Volledige tekst ›

Klachtenexploratie

Naar Volledige tekst ›

Ernstbeoordeling

Naar Volledige tekst ›

Lichamelijk en aanvullend onderzoek

Naar Volledige tekst ›

Evaluatie

Naar Volledige tekst ›

Richtlijnen beleid

Naar Volledige tekst ›

Voorlichting en advies & Niet-medicamenteuze behandeling

Naar Volledige tekst ›

Angstklachten

Naar Volledige tekst ›

Angststoornis, posttraumatische-stressstoornis of hypochondrie

Naar Volledige tekst ›

Medicamenteuze behandeling

Naar Volledige tekst ›

Keuze geneesmiddel

Naar Volledige tekst ›

Duur behandeling en afbouwen

Naar Volledige tekst ›

Afbouwen van SSRI’s

Naar Volledige tekst ›

Controles

Naar Volledige tekst ›

Verwijzing

Naar Volledige tekst ›

Belangrijkste wijzigingen

Naar Samenvatting ›

Kernboodschappen

Naar Samenvatting ›

Inleiding

Naar Samenvatting ›

Scope

Naar Samenvatting ›
Diagnostiek, behandeling en begeleiding
Naar Samenvatting ›

Afstemming

Naar Samenvatting ›

Achtergronden

Naar Samenvatting ›

Begrippen

Naar Samenvatting ›

Angstklachten en angststoornissen

Naar Samenvatting ›
Angst
Naar Samenvatting ›
Angstklachten
Naar Samenvatting ›
Abnormale angst
Naar Samenvatting ›
Paniekaanval
Naar Samenvatting ›
Angststoornissen
Naar Samenvatting ›
Posttraumatische-stressstoornis (PTSS)
Naar Samenvatting ›
Hypochondrie
Naar Samenvatting ›

Soorten angststoornissen

Naar Samenvatting ›
Paniekstoornis
Naar Samenvatting ›
Agorafobie
Naar Samenvatting ›
Specifieke fobie
Naar Samenvatting ›
Sociale fobie
Naar Samenvatting ›
Obsessieve-compulsieve stoornis (OCS)
Naar Samenvatting ›
Gegeneraliseerde-angststoornis
Naar Samenvatting ›

Epidemiologie

Naar Samenvatting ›

Etiologie en pathogenese

Naar Samenvatting ›
Leeftijd ontstaan
Naar Samenvatting ›

Risicogroepen

Naar Samenvatting ›

Vermijdingsgedrag

Naar Samenvatting ›

Beloop

Naar Samenvatting ›

Comorbiditeit

Naar Samenvatting ›

Richtlijnen diagnostiek

Naar Samenvatting ›

Inleiding

Naar Samenvatting ›

Veiligheid en aandacht

Naar Samenvatting ›

Signalen

Naar Samenvatting ›

Anamnese

Naar Samenvatting ›

Eerste oriëntatie

Naar Samenvatting ›

Klachtenexploratie

Naar Samenvatting ›

Algemeen

Naar Samenvatting ›

SCEGS

Naar Samenvatting ›
Somatische dimensie
Naar Samenvatting ›
Cognitieve dimensie
Naar Samenvatting ›
Emotionele dimensie
Naar Samenvatting ›
Gedragsmatige dimensie
Naar Samenvatting ›
Sociale dimensie
Naar Samenvatting ›

Vierdimensionale Klachtenlijst

Naar Samenvatting ›

Ernstbeoordeling

Naar Samenvatting ›

Lichamelijk en aanvullend onderzoek

Naar Samenvatting ›

Aanwijzingen somatische aandoening

Naar Samenvatting ›
Ouderen en somatische aandoeningen
Naar Samenvatting ›
Aanhoudende angst voor somatische aandoening
Naar Samenvatting ›

Gezamenlijke probleemdefinitie

Naar Samenvatting ›

Evaluatie

Naar Samenvatting ›

Richtlijnen beleid

Naar Samenvatting ›

Gepaste zorg

Naar Samenvatting ›
Behandelopties
Naar Samenvatting ›

Voorlichting en advies

Naar Samenvatting ›

Angstklachten

Naar Samenvatting ›

Angststoornis

Naar Samenvatting ›

Niet-medicamenteuze behandeling

Naar Samenvatting ›

Angstklachten

Naar Samenvatting ›

Angststoornissen

Naar Samenvatting ›

Cognitieve gedragstherapie (CGT)

Naar Samenvatting ›

Zelfhulp

Naar Samenvatting ›

Psychotherapie

Naar Samenvatting ›

Hypochondrie

Naar Samenvatting ›
CGT bij hypochondrie
Naar Samenvatting ›

Medicamenteuze behandeling

Naar Samenvatting ›

Inleiding

Naar Samenvatting ›

Keuze geneesmiddel

Naar Samenvatting ›

Start en opbouw

Naar Samenvatting ›

Bijwerkingen

Naar Samenvatting ›

Onvoldoende verbetering of non-respons

Naar Samenvatting ›

Duur behandeling en afbouwen

Naar Samenvatting ›
Afbouwen van SSRI’s
Naar Samenvatting ›
Adviezen
Naar Samenvatting ›
Tempo en doseringsstappen
Naar Samenvatting ›

Controles

Naar Samenvatting ›
Angstklachten
Naar Samenvatting ›
Angststoornis
Naar Samenvatting ›

Herstel en re-integratie/participatie

Naar Samenvatting ›

Terugvalpreventie

Naar Samenvatting ›

Consultatie en verwijzing

Naar Samenvatting ›

Referenties

  1. Karsten J, Hartman CA, Smit JH, Zitman FG, Beekman AT, Cuijpers P et al. Psychiatric history and subthreshold symptoms as predictors of the occurrence of depressive or anxiety disorder within 2 years. Br J Psychiatry 2011;198:206-12.
  2. Trimbos instituut. Herziening multidisciplinaire richtlijn Angststoornissen bij volwassenen: paniekstoornis en PTSS [eerste revisie]. Utrecht: Trimbos instituut, 2010.
  3. Trimbos instituut. Herziening multidisciplinaire richtlijn Angststoornissen bij volwassenen: sociale angststoornis [eerste revisie]. Utrecht: Trimbos instituut, 2011.
  4. KNMP, MIND, NHG, NVvP. Multidisciplinair document ‘Afbouwen SSRI’s & SNRI’s’ (2018). Ga naar bron
  5. Schoemaker C, Van Balkom AJLM, Van Gool CH, Gommer AM, Poos MJJC. Hoe vaak komen angststoornissen voor? RIVM, 2010. Ga naar bron
  6. De Graaf R, Ormel J, Ten Have M, Burger H, Buist-Bouwman M. Mental Disorders and service use in the Netherlands: Results from the European Study of the Epidemiology of Mental Disorders (ESEMeD). In: Kessler RC, Bedirhan Ustun T, editors. The WHO World Mental Health Surveys: Global Perspectives on the Epidemiology of Mental Disorders. Cambridge: Cambridge University Press, 2008: 388-405.
  7. De Graaf R, Ten Have M, Van Dorselaar S. De psychische gezondheid van de Nederlandse bevolking. Nemesis-2: opzet en eerste resultaten. Utrecht: Trimbos Instituut, 2010.
  8. Beekman ATF, Bremmer MA, Deeg DJH, Van Balkom AJLM, Smit JH, De Beurs E et al. Anxiety disorders in later life: a report from the longitudinal aging study Amsterdam. Int J Geriat Psychiatry 1998;13:717-26.
  9. Trimbos instituut. Addendum ouderen bij de Multidisciplinaire richtlijn Angststoornissen. Utrecht: Trimbos instituut, 2008.
  10. Van Balkom AJ, Beekman AT, De Beurs E, Deeg DJ, Van Dyck R, Van Tilburg W. Comorbidity of the anxiety disorders in a community-based older population in The Netherlands. Acta Psychiatr Scand 2000;101:37-45.
  11. Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry 2001;158:1568-78.
  12. McLeod BD, Wood JJ, Weisz JR. Examining the association between parenting and childhood anxiety: a meta-analysis. Clin Psychol Rev 2007;27:155-72.
  13. Van den Bosch WJHM, Treffers PE, redactie. Angststoornissen. Bijblijven 2004;20.
  14. Bienvenu OJ, Stein MB. Personality and anxiety disorders: a review. J Pers Disord 2003;17:139-51.
  15. Bienvenu OJ, Hettema JM, Neale MC, Prescott CA, Kendler KS. Low extraversion and high neuroticism as indices of genetic and environmental risk for social phobia, agoraphobia, and animal phobia. Am J Psychiatry 2007;164:1714-21.
  16. Khan AA, Jacobson KC, Gardner CO, Prescott CA, Kendler KS. Personality and comorbidity of common psychiatric disorders. Br J Psychiatry 2005;186:190-6.
  17. Hettema JM, Neale MC, Myers JM, Prescott CA, Kendler KS. A population-based twin study of the relationship between neuroticism and internalizing disorders. Am J Psychiatry 2006;163:857-64.
  18. Paris J. Predispositions, personality traits, and posttraumatic stress disorder. Harv Rev Psychiatry 2000;8:175-83.
  19. Bramsen I, Dirkzwager AJ, Van der Ploeg HM. Predeployment personality traits and exposure to trauma as predictors of posttraumatic stress symptoms: a prospective study of former peacekeepers. Am J Psychiatry 2000;157:1115-9.
  20. Jenike MA. Clinical practice. Obsessive-compulsive disorder. N Engl J Med 2004;350:259-65.
  21. Martin-Merino E, Ruigomez A, Wallander MA, Johansson S, Garcia-Rodriguez LA. Prevalence, incidence, morbidity and treatment patterns in a cohort of patients diagnosed with anxiety in UK primary care. Fam Pract 2010;27:9-16.
  22. Davis E, Saeed S, Antonacci D. Anxiety disorders in persons with developmental disabilities: empirically informed diagnosis and treatment. Psychiatr Q 2008;79:249-63.
  23. Smiley E. Epidemiology of mental health problems in adults with learning disabily: an update. Adv Psychiatric Treatment 2005;11:214-22.
  24. Borthwick-Duffy SA. Epidemiology and prevalence of psychopathology in people with mental retardation. J Consult Clin Psychol 1994;62:17-27.
  25. De Wit MA, Tuinebreijer WC, Dekker J, Beekman AJ, Gorissen WH, Schrier AC et al. Depressive and anxiety disorders in different ethnic groups: a population based study among native Dutch, and Turkish, Moroccan and Surinamese migrants in Amsterdam. Soc Psychiatry Psychiatr Epidemiol 2008;43:905-12.
  26. Steiner KH, Johansson SE, Sundquist J, Wändell PE. Self-reported anxiety, sleeping problems and pain among turkish-born immigrants in Sweden. Ethn Health 2007;12:363-79.
  27. Levecque K, Lodewyckx I, Vranken J. Depression and generalised anxiety in the general population in Belgium: a comparison between native and immigrant groups. J Affect Disord 2007;97:229-39.
  28. De Graaf R, Ten Have M, Van Dorselaar S, Schoemaker C, Beekman ATF, Vollebergh WA. Verschillen tussen etnische groepen in psychiatrische morbiditeit: resultaten van NEMESIS. MgV 2005;60:703-16.
  29. Ramsawh HJ, Raffa SD, Edelen MO, Rende R, Keller MB. Anxiety in middle adulthood: effects of age and time on the 14-year course of panic disorder, social phobia and generalized anxiety disorder. Psychol Med 2009;39:615-24.
  30. Yonkers KA, Bruce SE, Dyck IR, Keller MB. Chronicity, relapse, and illness--course of panic disorder, social phobia, and generalized anxiety disorder: findings in men and women from 8 years of follow-up. Depress Anxiety 2003;17:173-9.
  31. Perkonigg A, Pfister H, Stein MB, Hofler M, Lieb R, Maercker A et al. Longitudinal course of posttraumatic stress disorder and posttraumatic stress disorder symptoms in a community sample of adolescents and young adults. Am J Psychiatry 2005;162:1320-7.
  32. Olde Hartman TC, Borghuis MS, Lucassen PL, Van de Laar FA, Speckens AE, Van Weel C. Medically unexplained symptoms, somatisation disorder and hypochondriasis: course and prognosis. A systematic review. J Psychosom Res 2009;66:363-77.
  33. Stein MB, Roy-Byrne PP, Craske MG, Bystritsky A, Sullivan G, Pyne JM et al. Functional impact and health utility of anxiety disorders in primary care outpatients. Med Care 2005;43:1164-70.
  34. Laitinen-Krispijn S, Bijl RV. Mental disorders and employee sickness absence: the NEMESIS study. Netherlands Mental Health Survey and Incidence Study. Soc Psychiatry Psychiatr Epidemiol 2000;35:71-7.
  35. Michon HW, Ten Have M, Kroon H, Van Weeghel J, De Graaf R, Schene AH. Mental disorders and personality traits as determinants of impaired work functioning. Psychol Med 2008;38:1627-37.
  36. Waghorn G, Chant D, White P, Whiteford H. Disability, employment and work performance among people with ICD-10 anxiety disorders. Aust N Z J Psychiatry 2005;39:55-66.
  37. Kouzis AC, Eaton WW. Emotional disability days: prevalence and predictors. Am J Public Health 1994;84:1304-7.
  38. Kessler RC, Frank RG. The impact of psychiatric disorders on work loss days. Psychol Med 1997;27:861-73.
  39. Dewa CS, Lin E. Chronic physical illness, psychiatric disorder and disability in the workplace. Soc Sci Med 2000;51:41-50.
  40. Hirschfeld RM. The comorbidity of major depression and anxiety disorders: recognition and management in primary care. Prim Care Companion J Clin Psychiatry 2001;3:244-54.
  41. Sareen J, Cox BJ, Afifi TO, De Graaf R, Asmundson GJG, Ten Have M et al. Anxiety disorders and risk for suicidal ideation and suicide attempts: A population-based longitudinal study of adults. Arch Gen Psychiatry 2005c;62:1249-57.
  42. Van Balkom AJ, Van Boeijen CA, Boeke AJ, Van Oppen P, Kempe PT, Van Dyck R. Comorbid depression, but not comorbid anxiety disorders, predicts poor outcome in anxiety disorders. Depress Anxiety 2008;25:408-15.
  43. Sareen J, Cox BJ, Clara I, Asmundson GJ. The relationship between anxiety disorders and physical disorders in the U.S. National Comorbidity Survey. Depress Anxiety 2005a;21:193-202.
  44. Trimbos instituut. Multidisciplinaire richtlijn Angststoornissen. Utrecht: Trimbos instituut, 2003.
  45. Limburg-Okken A, Lutjenhuis M, i.s.m.GGD Den Haag. Handreiking voor een anamnestisch gesprek met migranten bij verholen psychosociale problemen. Den Haag: GGD Den Haag Stafbureau Epidemiologie, 1989.
  46. Kirmayer LJ, Robbins JM, Dworkind M, Yaffe MJ. Somatization and the recognition of depression and anxiety in primary care. Am J Psychiatry 1993;150:734-41.
  47. Sareen J, Chartier M, Kjernisted KD, Stein MB. Comorbidity of phobic disorders with alcoholism in a Canadian community sample. Can J Psychiatry 2001;46:733-40.
  48. Alegria AA, Hasin DS, Nunes EV, Liu SM, Davies C, Grant BF et al. Comorbidity of generalized anxiety disorder and substance use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2010;71:1187-95.
  49. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) study. JAMA 1990;264:2511-8.
  50. Jacobsen LK, Southwick SM, Kosten TR. Substance use disorders in patients with posttraumatic stress disorder: A review of the literature. Am J Psychiatry 2001;158:1184-90.
  51. Schneier FR, Foose TE, Hasin DS, Heimberg RG, Liu SM, Grant BF et al. Social anxiety disorder and alcohol use disorder co-morbidity in the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med 2010;40:977-88.
  52. Marquenie LA, Schade A, Van Balkom AJLM, Comijs HC, De Graaf R, Vollebergh W et al. Origin of the comorbidity of anxiety disorders and alcohol dependence: findings of a general population study. Eur Addict Res 2007;13:39-49.
  53. Schade A, Marquenie LA, Van Balkom AJLM, Koeter MMJ, Van den Brink W, Van Dyck R. Effectiviteit van een toegevoegde behandeling voor angstklachten bij alcoholafhankelijke patiënten met een fobische stoornis. Tijdschr Psychiatr 2008;50:137-48.
  54. Pilowsky DJ, Olfson M, Gameroff MJ, Wickramaratne P, Blanco C, Feder A et al. Panic disorder and suicidal ideation in primary care. Depress Anxiety 2006;23:11-6.
  55. Sareen J, Cox BJ, Stein MB, Afifi TO, Fleet C, Asmundson GJG. Physical and mental comorbidity, disability, and suicidal behavior associated with posttraumatic stress disorder in a large community sample. Psychosom Med 2007;69:242-8.
  56. Terluin B. De vierdimensionale klachtenlijst. Huisarts Wet 1996;39:538-47.
  57. Terluin B, Terluin M, Prince K, Van Marwijk H. De Vierdimensionale Klachtenlijst (4DKL) spoort psychische problemen op. Huisarts Wet 2008;51:251-5.
  58. Terluin B, Brouwers EP, Van Marwijk HW, Verhaak PF, Van der Horst HE. Detecting depressive and anxiety disorders in distressed patients in primary care; comparative diagnostic accuracy of the Four-Dimensional Symptom Questionnaire (4DSQ) and the Hospital Anxiety and Depression Scale (HADS). BMC Fam Pract 2009;10:58.
  59. Lipowski ZJ. Somatization: the concept and its clinical application. Am J Psychiatry 1988;145:1358-68.
  60. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). Washington: APA, 2000.
  61. Luborsky L, Rosenthal R, Diguer L, Andrusyna TP, Berman JS, Levitt J et al. The dodo bird verdict is alive and well - mostly. Clin Psychol Sci Pract 2002;9:2-12.
  62. Wampold BE. Allegiance and adherence: further evidence for the contextual model. In: Wampold BE, editor. The great psychotherapy debate: models, methods, and findings. Mahwak, New Yersey: Lawrence Erlbaum Associates, 2001: 159-83.
  63. Hubble MA, Duncan BL, Miller SD. The heart and soul of change. What works in therapy. Washington DC: American Psychological Association, 1999.
  64. Lambert MJ, Barley DE. Research summary on the therapeutic relationship and psychotherapy outcome. Psychotherapy 2001;38:357-61.
  65. Lambert MJ. Implication of psychotherapy outcome research for psychotehrapy integration. In: Norcross JC, Goldfield MR, editors. Handbook of Psychotherapy Integration. Oxford: Oxford University Press, 2003.
  66. Levinson W, Roter D. Physicians’ psychosocial beliefs correlate with their patient communication skills. J Gen Intern Med 1995;10:375-9.
  67. Cape J, Whittington C, Buszewicz M, Wallace P, Underwood L. Brief psychological therapies for anxiety and depression in primary care: meta-analysis and meta-regression. BMC Med 2010;8:38.
  68. Hassink-Franke LJA. Problem-solving treatment during general practice residency - Feasibility, and effectiveness for patiënts with emotional symptoms in primary care. Nijmegen: Radboud Universiteit, 2010.
  69. Norton PJ, Price EC. A meta-analytic review of adult cognitive-behavioral treatment outcome across the anxiety disorders. J Nerv Ment Dis 2007;195:521-31.
  70. Mitte K. A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia. J Affect Disord 2005;88:27-45.
  71. Hunot V, Churchill R, Silva de Lima M, Teixeira V. Psychological therapies for generalised anxiety disorder. Cochrane Database Syst Rev 2007;CD001848.
  72. Fedoroff IC, Taylor S. Psychological and pharmacological treatments of social phobia: a meta-analysis. J Clin Psychopharmacol 2001;21:311-24.
  73. Gava I, Barbui C, Aguglia E, Carlino D, Churchill R, De Vanna M et al. Psychological treatments versus treatment as usual for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev 2007;CD005333.
  74. Saeed SA, Antonacci DJ, Bloch RM. Exercise, yoga, and meditation for depressive and anxiety disorders. Am Fam Physician 2010;81:981-6.
  75. Hofmann SG, Sawyer AT, Witt AA, Oh D. The effect of mindfulness-based therapy on anxiety and depression: A meta-analytic review. J Consult Clin Psychol 2010;78:169-83.
  76. Carlbring P, Nilsson-Ihrfelt E, Waara J, Kollenstam C, Buhrman M, Kaldo V et al. Treatment of panic disorder: live therapy vs. self-help via the Internet. Behav Res Ther 2005;43:1321-33.
  77. Klein B, Richards JC, Austin DW. Efficacy of internet therapy for panic disorder. J Behav Ther Exp Psychiatry 2006;37:213-38.
  78. Hirai M, Clum GA. A meta-analytic study of self-help interventions for anxiety problems. Behav Ther 2006;37:99-111.
  79. Rapee RM, Abbott MJ, Baillie AJ, Gaston JE. Treatment of social phobia through pure self-help and therapist-augmented self-help. Br J Psychiatry 2007;191:246-52.
  80. Furmark T, Carlbring P, Hedman E, Sonnenstein A, Clevberger P, Bohman B et al. Guided and unguided self-help for social anxiety disorder: randomised controlled trial. Br J Psychiatry 2009;195:440-7.
  81. Knaevelsrud C, Maercker A. Internet-based treatment for PTSD reduces distress and facilitates the development of a strong therapeutic alliance: a randomized controlled clinical trial. BMC Psychiatry 2007;7:13.
  82. Litz BT, Engel CC, Bryant RA, Papa A. A randomized, controlled proof-of-concept trial of an Internet-based, therapist-assisted self-management treatment for posttraumatic stress disorder. Am J Psychiatry 2007;164:1676-83.
  83. Tolin DF, Hannan S, Maltby N, Diefenbach GJ, Worhunsky P, Brady RE. A randomized controlled trial of self-directed versus therapist-directed cognitive-behavioral therapy for obsessive-compulsive disorder patients with prior medication trials. Behav Ther 2007;38:179-91.
  84. Richards A, Barkham M, Cahill J, Richards D, Williams C, Heywood P. PHASE: a randomised, controlled trial of supervised self-help cognitive behavioural therapy in primary care. Br J Gen Pract 2003;53:764-70.
  85. Proudfoot J, Ryden C, Everitt B, Shapiro DA, Goldberg D, Mann A et al. Clinical efficacy of computerised cognitive-behavioural therapy for anxiety and depression in primary care: randomised controlled trial. Br J Psychiatry 2004;185:46-54.
  86. Craske MG, Rose RD, Lang A, Welch SS, Campbell-Sills L, Sullivan G et al. Computer-assisted delivery of cognitive behavioral therapy for anxiety disorders in primary-care settings. Depress Anxiety 2009;26:235-42.
  87. Van Boeijen CA, Van Balkom AJ, Van Oppen P, Blankenstein N, Cherpanath A, Van Dyck R. Efficacy of self-help manuals for anxiety disorders in primary care: a systematic review. Fam Pract 2005;22:192-6.
  88. Bandelow B, Seidler-Brandler U, Becker A, Wedekind D, Ruther E. Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. World J Biol Psychiatry 2007;8:175-87.
  89. Furukawa TA, Watanabe N, Churchill R. Combined psychotherapy plus antidepressants for panic disorder with or without ago­raphobia. Cochrane Database Syst Rev 2007;CD004364.
  90. Blomhoff S, Haug TT, Hellstrom K, Holme I, Humble M, Madsbu HP et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry 2001;179:23-30.
  91. Davidson JRT, Foa EB, Huppert JD, Keefe FJ, Franklin ME, Compton JS et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry 2004;61:1005-13.
  92. Clark DM, Ehlers A, McManus F, Hackmann A, Fennell M, Campbell H et al. Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. J Consult Clin Psychol 2003;71:1058-67.
  93. Thomson AB, Page LA. Psychotherapies for hypochondriasis. Cochrane Database Syst Rev 2007;CD006520.
  94. Greeven A, Van Balkom AJLM, Van der Leeden R, Merkelbach JW, Van den Heuvel OA, Spinhoven P. Cognitive behavioral therapy versus paroxetine in the treatment of hypochondriasis: an 18-month naturalistic follow-up. J Behav Ther Exp Psychiatry 2009;40:487-96.
  95. Greeven A, Van Balkom AJ, Visser S, Merkelbach JW, Van Rood YR, Van Dyck R et al. Cognitive behavior therapy and paroxetine in the treatment of hypochondriasis: a randomized controlled trial. Am J Psychiatry 2007;164:91-9
  96. Davidson JR. Pharmacotherapy of social anxiety disorder: what does the evidence tell us? J Clin Psychiatry 2006;67 Suppl 12:20-6.
  97. Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie (KNMP). Psychofarmaca. Informatorium Medicamentorum. Den Haag: KNMP, 2011: 1015-102.
  98. Kwaliteitsinstituut voor de Gezondheidszorg CBO. Conceptrichtlijn Osteoporose en fractuurpreventie, derde herziening (2010). Ga naar bron
  99. Ryding E, Lindstrom M, Traskman-Bendz L. The role of dopamine and serotonin in suicidal behaviour and aggression. Prog Brain Res 2008;172:307-15.
  100. Krakowski M. Violence and serotonin: influence of impulse control, affect regulation, and social functioning. J Neuropsychiatry Clin Neurosci 2003;15:294-305.
  101. Healy D, Herxheimer A, Menkes DB. Antidepressants and violence: problems at the interface of medicine and law. PLoS Med 2006;3:e372.
  102. Okada F, Okajima K. Violent acts associated with fluvoxamine treatment. J Psychiatry Neurosci 2001;26:339-40.
  103. Breggin PR. Suicidality, violence and mania caused by selective serotonin reuptake inhibitors (ssris): A review and analysis. Int J Risk Saf Med 2003;16:31-49.
  104. Tauscher-Wisniewski S, Nilsson M, Caldwell C, Plewes J, Allen AJ. Meta-analysis of aggression and/or hostility-related events in children and adolescents treated with fluoxetine compared with placebo. J Child Adolesc Psychopharmacol 2007;17:713-8.
  105. Walsh MT, Dinan TG. Selective serotonin reuptake inhibitors and violence: a review of the available evidence. Acta Psychiatr Scand 2001;104:84-91.
  106. Goedhard LE, Stolker JJ, Heerdink ER, Nijman HL, Olivier B, Egberts TC. Pharmacotherapy for the treatment of aggressive behavior in general adult psychiatry: A systematic review. J Clin Psychiatry 2006;67:1013-24.
  107. Stein DJ, Ipser J, Seedat S. Pharmacotherapy for posttraumatic stress disorder. Cochrane Database Syst Rev 2006;CD002795.
  108. Stein DJ, Ipser JC, Balkom AJ. Pharmacotherapy for social phobia. Cochrane Database Syst Rev 2004;CD001206.
  109. Kapczinski F, Lima MS, Souza JS, Schmitt R. Antidepressants for generalized anxiety disorder. Cochrane Database Syst Rev 2003;CD003592.
  110. Bakker A, Van Balkom AJ, Spinhoven P. SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatr Scand 2002;106:163-7.
  111. Taylor CB. Panic disorder. BMJ 2006;332:951-5.
  112. Katon WJ. Panic Disorder. N Engl J Med 2006;354:2360-7.
  113. Roy-Byrne PP, Craske MG, Stein MB. Panic disorder. Lancet 2006;368:1023-32.
  114. Bakker A, Van Balkom AJLM, Stein DJ. Evidence-based pharmacotherapy of panic disorder. Int J Neuropsychopharmacol 2005;8:473-82.
  115. Vieweg WV, Julius DA, Fernandez A, Beatty-Brooks M, Hettema JM, Pandurangi AK. Posttraumatic stress disorder: clinical features, pathophysiology, and treatment. Am J Med 2006;119:383-90.
  116. Freedy JR, Brock CD. Spotting-and treating-PTSD in primary care. J Fam Pract 2010;59:75-80.
  117. Forbes D, Creamer MC, Phelps AJ, Couineau AL, Cooper JA, Bryant RA et al. Treating adults with acute stress disorder and post-traumatic stress disorder in general practice: a clinical update. Med J Aust 2007b;187:120-3.
  118. Heyman I, Mataix-Cols D, Fineberg NA. Obsessive-compulsive disorder. BMJ 2006;333:424-9.
  119. Fricchione G. Clinical practice. Generalized anxiety disorder. N Engl J Med 2004;351:675-82.
  120. Tyrer P, Baldwin D. Generalised anxiety disorder. Lancet 2006;368:2156-66.
  121. Stein MB, Stein DJ. Social anxiety disorder. Lancet 2008;371:1115-25.
  122. Culpepper L. Social anxiety disorder in the primary care setting. J Clin Psychiatry 2006;67 Suppl 12:31-7.
  123. Schneier FR. Clinical practice. Social anxiety disorder. N Engl J Med 2006;355:1029-36.
  124. Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2008;27:31-40.
  125. Stone M, Laughren T, Jones ML, Levenson M, Holland PC, Hughes A, et al. Risk of suicidality in clinical trials of antidepressants in adults: Analysis of proprietary data submitted to us food and drug administration. BMJ 2009;339:b2880.
  126. Carpenter DJ, Fong R, Kraus JE, Davies JT, Moore C, Thase ME. Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: A complete set of randomized placebo-controlled trials. J Clin Psychiatry 2011;72:1503-14.
  127. Vanderburg DG, Batzar E, Fogel I, Kremer CM. A pooled analysis of suicidality in double-blind, placebo-controlled studies of sertraline in adults. J Clin Psychiatry 2009;70:674-83.
  128. Martinez C, Rietbrock S, Wise L, Ashby D, Chick J, Moseley J, et al. Antidepressant treatment and the risk of fatal and non-fatal self-harm in first episode depression: Nested case-control study. BMJ 2005;330:389.
  129. Umetsu R, Abe J, Ueda N, Kato Y, Matsui T, Nakayama Y, et al. Association between selective serotonin reuptake inhibitor therapy and suicidality: Analysis of U.S. Food and Drug administration adverse event reporting system data. Biol Pharm Bull 2015;38:1689-99.
  130. Pollock BG. Adverse reactions of antidepressants in elderly patients. J Clin Psychiatry 1999;60 Suppl 20:4-8.
  131. Wijnen HH, Van Schendel FM, Olde Rikkert MG, Van der Hooft CS, Van Puijenbroek EP. Hyponatriëmie bij gebruik van selectieve serotonineheropnameremmers: meldingen in 1992-2002. Ned Tijdschr Geneeskd 2004;148:1921-4.
  132. Ministerie van VWS. HARM-WRESTLING. Een voorstel van de Expertgroep Medicatieveiligheid m.b.t. concrete interventies die de extramurale medicatieveiligheid op korte termijn kunnen verbeteren. Den Haag: Ministerie van VWS, 2009.
  133. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 2001;61:2163-75.
  134. Boyer EW, Shannon M. The Serotonin Syndrome. New Engl J Med 2005;352:1112-20.
  135. Bijl D, Verduijn M. Antidepressiva tijdens zwangerschap en borstvoeding. Geneesmiddelen Bulletin 2007;41:59-67.
  136. Argento A, Tiraferri E, Marzaloni M. Anticoagulanti orali e piante medicinali. Una interazione emergente. Ann Ital Med Int 2000;15:139-43.
  137. Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA 2001;286:208-16.
  138. Gorgels WJMJ, Oude Voshaar RC, Mol AJJ, Breteler MHM, Van de Lisdonk EH, Zitman FG. Het langdurig gebruik van benzodiazepinen. Ned Tijdschr Geneeskd 2001;145:1342-6.
  139. Lee CW, Drummond PD. Effects of eye movement versus therapist instructions on the processing of distressing memories. J Anxiety Disord 2008;22:801-8.
  140. Bisson J, Andrew M. Psychological treatment of post-traumatic stress disorder (PTSD). Cochrane Database Syst Rev 2007;CD003388.
  141. Raboni MR, Tufik S, Suchecki D. Treatment of PTSD by eye movement desensitization reprocessing (EMDR) improves sleep quality, quality of life, and perception of stress. Ann N Y Acad Sci 2006;1071:508-13.
  142. Van der Kolk BA, Spinazzola J, Blaustein ME, Hopper JW, Hopper EK, Korn DL et al. A randomized clinical trial of eye movement desensitization and reprocessing (EMDR), fluoxetine, and pill placebo in the treatment of posttraumatic stress disorder: treatment effects and long-term maintenance. J Clin Psychiatry 2007;68:37-46.
  143. Forbes D, Creamer M, Phelps A, Bryant R, McFarlane A, Devilly GJ et al. Australian guidelines for the treatment of adults with acute stress disorder and post-traumatic stress disorder. Aust N Z J Psychiatry 2007a;41:637-48.
  144. Roberts NP, Kitchiner NJ, Kenardy J, Bisson J. Multiple session early psychological interventions for the prevention of post-traumatic stress disorder. Cochrane Database Syst Rev 2009;CD006869.
NHG-werkgroep Angst
6 gerelateerde lacunes6 gerelateerde onderzoeken
E-mail